DNA immunotherapy for recurrent respiratory papillomatosis (RRP): phase 1/2 study assessing efficacy, safety, and immunogenicity of INO-3107.
Saved in:
| Title: | DNA immunotherapy for recurrent respiratory papillomatosis (RRP): phase 1/2 study assessing efficacy, safety, and immunogenicity of INO-3107. |
|---|---|
| Authors: | Morrow MP; Inovio Pharmaceuticals, Plymouth Meeting, PA, USA. Matthew.Morrow@inovio.com., Gillespie E; Inovio Pharmaceuticals, Plymouth Meeting, PA, USA., Sylvester A; Inovio Pharmaceuticals, Plymouth Meeting, PA, USA., Amin MR; Department of Otolaryngology-Head and Neck Surgery, New York University Grossman School of Medicine, New York, New York, NY, USA., Belafsky PC; Department of Otolaryngology/Head and Neck Surgery, Davis School of Medicine, University of California, Sacramento, CA, USA., Best SR; Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Friedman AD; Division of Laryngology, Department of Otolaryngology-Head and Neck Surgery, University of Cincinnati Medical Center, Cincinnati, OH, USA., Klein AM; Department of Otolaryngology-Head and Neck Surgery, Emory University, Atlanta, GA, USA., Lott DG; Division of Laryngology, Mayo Clinic Arizona, Phoenix, AZ, USA., Mau T; Department of Otolaryngology-Head and Neck Surgery, Voice Center, University of Texas Southwestern Medical Center, Dallas, TX, USA., Paniello RC; Department of Otolaryngology - Head and Neck Surgery, Washington University School of Medicine, St. Louis, MO, USA., Pransky SM; Pediatric Specialty Partners, San Diego, CA, USA., Saba NF; Department of Hematology and Medical Oncology, The Winship Cancer Institute, Emory University, Atlanta, GA, USA., Tan GS; Inovio Pharmaceuticals, Plymouth Meeting, PA, USA., Wisotsky S; Inovio Pharmaceuticals, Plymouth Meeting, PA, USA., Marcus SA; Inovio Pharmaceuticals, Plymouth Meeting, PA, USA., Reuschel EL; Inovio Pharmaceuticals, Plymouth Meeting, PA, USA., Reed KS; Inovio Pharmaceuticals, Plymouth Meeting, PA, USA., Weiner DB; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA, USA., Dallas M; Inovio Pharmaceuticals, Plymouth Meeting, PA, USA., Skolnik JM; Inovio Pharmaceuticals, Plymouth Meeting, PA, USA. |
| Source: | Nature communications [Nat Commun] 2025 Feb 12; Vol. 16 (1), pp. 1518. Date of Electronic Publication: 2025 Feb 12. |
| Publication Type: | Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2041-1723 |
|---|---|
| DOI: | 10.1038/s41467-025-56729-6 |
